Keywords
How to Cite
Abstract
Background. The analysis of circulating tumor DNA provides wide opportunities for monitoring the results of cancer treatment. Somatic mutations in TP53 gene are present in almost all breast carcinomas developing in hereditary BRCA1 mutation carriers, as well as in the majority of high-grade serous ovarian tumors, which makes it possible to use them for effective monitoring of these diseases.
The aim of the study was to analyze the content of tumor-specific TP53 mutations in plasma of patients with high-grade serous ovarian cancer (OC) and BRCA1-associated breast cancer (BC).
Materials and methods. At least one plasma sample was obtained from 10 patients with OC and 7 patients with BRCA1-associated BC. The primary intratumoral status of TP53 gene was determined in the archival tumor material by targeted next generation sequencing. Digital droplet PCR was applied for testing of plasma samples for the presence of tumor-specific TP53 mutations, and in one case, BRAF V600E mutation.
Results. All 8 plasma samples obtained from OC patients at the time of disease progression, before or during neoadjuvant chemotherapy, were positive for TP53 mutations. In contrast, 8 OC plasma samples obtained during remission, after surgery, or after neoadjuvant chemotherapy did not contain tumor-specific mutations. In breast cancer, circulating tumor DNA was detected in 2 of 4 samples obtained before treatment, and was not detected after the end of therapy or in remission.
Conclusion. There is a good correlation between the presence of tumor-specific TP53 mutations in circulating DNA and the disease status in OC patients, therefore TP53 is a promising marker for clinical monitoring of ovarian cancer. In breast cancer, circulating tumor DNA is less abundant, therefore TP53 mutations cannot be reliably detected by digital droplet PCR in the plasma of patients with moderate disease burden.
References
Barbosa A., Peixoto A., Pinto P. et al. Potential clinical applications of circulating cell-free DNA in ovarian cancer patients. Expert Rev. Mol. Med. 2018; 20:e6. doi: 10.1017/erm.2018.5.
Manié E., Vincent-Salomon A., Lehmann-Che J. et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res. 2009;69(2): 663-671. doi: 10.1158/0008-5472.CAN-08-1560.
Ahmed A.A., Etemadmoghadam D., Temple J. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 2010;221(1):49-56.
Rowlands V., Rutkowski A.J., Meuser E. et al. Optimisation of robust singleplex and multiplex droplet digital PCR assays for high confidence mutation detection in circulating tumour DNA. Sci. Rep. 2019;9(1):12620. doi: 10.1038/s41598-019-49043-x.
Pereira E., Camacho-Vanegas O., Anand S. et al. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers. PLoS One. 2015;10(12):e0145754. doi: 10.1371/journal.pone.0145754.
Parkinson C.A., Gale D., Piskorz A.M. et al. Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study. PLoS Med. 2016;13(12):e1002198. doi: 10.1371/journal.pmed.1002198.
Kim Y.M., Lee S.W., Lee Y.J. et al. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma. J. Gynecol. Oncol. 2019;30(3):e32. doi: 10.3802/jgo.2019.30.e32.
Vitale S.R., Groenendijk F.H., van Marion R. et al. TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer. Biomolecules. 2020;10(3):415. doi: 10.3390/biom10030415.
Noguchi T., Sakai K., Iwahashi N. et al. Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian cancer. Oncol. Lett. 2020;19(4):2713-2720. doi: 10.3892/ol.2020.11356.
Alimirzaie S., Bagherzadeh M., Akbari M.R. Liquid biopsy in breast cancer: A comprehensive review. Clin. Genet. 2019;95(6): 643-660. doi: 10.1111/cge.13514.
Dawson S.J., Tsui D.W., Murtaza M. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 2013;368(13):1199-1209. doi: 10.1056/NEJMoa1213261.
Madic J., Kiialainen A., Bidard F.C. et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int. J. Cancer. 2015;136(9):2158-2165. doi: 10.1002/ijc.29265.
Liang D.H., Ensor J.E., Liu Z.B. et al. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients. Breast Cancer Res. Treat. 2016;155(1): 139-149. doi: 10.1007/s10549-015-3635-5.
Nakauchi C., Kagara N., Shimazu K. et al. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing. Clin. Breast Cancer. 2016;16(5):418-423. doi: 10.1016/j.clbc.2016.05.004.
Rossi G., Mu Z., Rademaker A.W. et al. Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer. Clin. Cancer Res. 2018;24(3): 560-568. doi: 10.1158/1078-0432.CCR-17-2092.
O'Leary B., Hrebien S., Morden J.P. et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat. Commun. 2018;9(1):896. doi: 10.1038/s41467-018-03215-x.
Armbruster D.A., Pry T. Limit of blank, limit of detection and limit of quantitation. Clin. Biochem. Rev. 2008;29 Suppl 1(Suppl 1): S49-52.
Riva F., Bidard F.C., Houy A. et al. Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Clin. Chem. 2017;63(3): 691-699. doi: 10.1373/clinchem.2016.262337.
McDonald B.R., Contente-Cuomo T., Sammut S.J. et al. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Sci. Transl. Med. 2019;11(504): pii: eaax7392. doi: 10.1126/scitranslmed.aax7392.
Butler T.M., Boniface C.T., Johnson-Camacho K. et al. Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer. Cold Spring Harb. Mol. Case Stud. 2019;5(2):pii: a003772. doi: 10.1101/mcs.a003772.
Rothé F., Silva M.J., Venet D. et al. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. Clin. Cancer Res. 2019;25(12): 3581-3588. doi: 10.1158/1078-0432.CCR-18-2521.
Garcia-Murillas I., Chopra N., Comino-Méndez I. et al. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. JAMA Oncol. 2019. doi: 10.1001/jamaoncol.2019.1838.
Stover D.G., Parsons H.A., Ha G. et al. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J. Clin. Oncol. 2018;36(6): 543-553. doi: 10.1200/JCO.2017.76.0033.
Beddowes E., Sammut S.J., Gao M., Caldas C. Predicting treatment resistance and relapse through circulating DNA. Breast. 2017;34 Suppl 1:S31-S35. doi: 10.1016/j.breast.2017.06.024.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021